French drugmaker Valneva said on Wednesday it will conduct a trial about the use of its COVID-19 vaccine candidate VLA2001 as a booster jab following a mRNA vaccination or natural infection.

Summary. Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Ixiaro generated roughly €94.1 million in 2024 and remains Valneva’s main ...

Valneva obtains exclusive worldwide license for LimmaTech’s S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva’s R&D pipeline LimmaTech to receive upfront ...

Among the adopted resolutions were the approval of the 2024 financial statements, delegations for the Board of Directors to increase Valneva’s share capital and/or issue financial instruments, the ...

Saint Herblain (France), April 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S ...

Saint-Herblain (France), November 9, 2023 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported consolidated financial results for the first nine months of ...

Valneva’s chief medical officer Juan Carlos Jaramillo said: “We reiterate our support for the precautionary measures that have been taken as well as our commitment to continue monitoring all ...

Valneva SE is a French biotechnology company specializing in developing and commercializing vaccines. We expect approval of two attractive vaccine candidates targeting Chikungunya and Lyme disease ...

This release contains forward-looking information about an investigational Lyme disease vaccine candidate, VLA15, and a collaboration between Pfizer and Valneva for VLA15, including their ...

Shares of Valneva VALN have plunged 52.9% in the trailing 12 months compared with the industry’s 33.8% decline. This substantial decline was caused by the revision of the advance purchase ...